Autophagy Antibody Panel Reference: ARG30321 Autophagy antibody; SQSTM1 / p62 antibody; LC3B antibody; Beclin 1 antibody; GAPDH antibody
Ifabotuzumab Reference: HY-P99655 Ifabotuzumab (KB004) is an IgG1κ antibody targeting EphA3 (KD=610 pM). Ifabotuzumab induces tumor cell apoptosis, activates Antibody-dependent cell mediated cytotoxicity (ADCC), and damages tumor vasculature. Ifabotuzumab reduces human idiopathic pulmonary fibrosis (IPF) CCR10+ cells and improves pulmonary fibrosis.
Odronextamab Reference: HY-P99038 Odronextamab is a hinge-stabilised, fully human IgG4-based CD20 × CD3 bispecific antibody that binds CD3 on T cells and CD20 on B cells.
Inflammation Antibody Panel Reference: ARG30323 Inflammation antibody; NFkB p65 phospho (Ser536) antibody; COX2 antibody; iNOS antibody; beta Actin antibody
Secukinumab Reference: HY-P9927 Secukinumab (AIN457) is a high affinity, human monoclonal antibody targeted against interleukin (IL)-17A. Secukinumab is the first-in-class anti-IL-17 agent used for the research of plaque psoriasis, ankylosing spondylitis and psoriatic arthritis.
Neuroinflammation Antibody Panel Reference: ARG30324 Neuroinflammation antibody; CD68 antibody; AIF1 / Iba 1 antibody; GFAP antibody
Nesvacumab Reference: HY-P99036 Nesvacumab is a fully human immunoglobulin G1 (IgG1) monoclonal antibody that specifically binds and inactivates the Tie2 receptor ligand Angiopoietin-2 (Ang2) with high affinity, but shows no binding to Ang1.
Inflammatory Cell Antibody Panel Reference: ARG30325 Inflammatory Cell antibody; MPO / Myeloperoxidase antibody; CD3 antibody; CD20 antibody; CD68 antibody
Tiragolumab Reference: HY-P9986 Tiragolumab is an immune checkpoint inhibitor binding to T-cell immunoglobulin and ITIM domain (TIGIT). Tiragolumab, alone or in combination with the PD-L1 inhibitor Atezolizumab, may be effective against multiple solid malignancies-most notably non-small cell lung cancer.
Inflammatory Cell Antibody Panel (for mouse) Reference: ARG30326 Inflammatory Cell antibody; Ly6G + Ly6C antibody; EMR1 F4/80 antibody; CD3 antibody; CD45R / B220 antibody
Rosopatamab Reference: HY-P99239 Rosopatamab (HJ 591) is a humanised anti-PSMA monoclonal antibody that can be used in cancer research, particularly in prostate cancer.